Compare Carvana Co (CVNA) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Novartis AG — how do they compare? Carvana Co trades at $70.57 (market cap $79.17B), while Novartis AG trades at $152.83 (market cap $295.37B). The key difference: Novartis AG is far larger — about 3.7× Carvana Co's market cap, and Novartis AG pays a 3.07% dividend while Carvana Co pays none. Which is the better fit depends on your goals.
| CVNA | NVS | |
|---|---|---|
Market Cap | $79.17B | $295.37B |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $168.62 |
52-Week Low | $56.27 | $119.31 |
Enterprise Value | $81.65B | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $74.20, up 4.73% today, with strong recent earnings beats and bullish technical signals. Revenue surged 52% year-over-year in Q2 2026 to $7.38 billion, while net income reached a record $513 million. The stock faces valuation concerns with a P/E of 38.1 and EV/EBITDA of 575.03, but positive cash flow trends and analyst consensus support growth prospects.
The outlook remains optimistic due to robust unit growth and AI-driven cost efficiencies, though risks include profit margin compression and high debt levels. With a consensus price target of $87.18, upside potential exists if execution continues, but investors should monitor competitive pressures and macroeconomic headwinds.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
